Using Modeling and Simulation to Combat a Global Health Priority

The Critical Path to TB Drug Regimens (CPTR) Initiative is working collaboratively to speed the development of new tuberculosis treatments with the aim of reducing their duration through novel methods of development and deployment. CPTR/C-Path partnered with Certara to develop a mechanistic, multi-compartment, permeability-limited physiologically-based pharmacokinetic (PBPK) model of the human lung. The multi-compartment lung and granuloma PBPK model provides a framework for investigating the impact of inter-individual variability on pharmacokinetics and local drug concentration on killing mycobacteria.

Learn More
LinkedIn